JP2013542720A - 抗エフリン−ｂ２抗体およびその使用 - Google Patents

抗エフリン−ｂ２抗体およびその使用 Download PDF

Info

Publication number
JP2013542720A
JP2013542720A JP2013528731A JP2013528731A JP2013542720A JP 2013542720 A JP2013542720 A JP 2013542720A JP 2013528731 A JP2013528731 A JP 2013528731A JP 2013528731 A JP2013528731 A JP 2013528731A JP 2013542720 A JP2013542720 A JP 2013542720A
Authority
JP
Japan
Prior art keywords
antibody
polypeptide
ephrin
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013528731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542720A5 (https=
Inventor
トレクアドラダ，ホルヘ ルイス マルティネス
インファンテス，マリア アンヘレス アベンゴザール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion Centro Nacional De Investigaciones Oncologicas Cnio
Original Assignee
Fundacion Centro Nacional De Investigaciones Oncologicas Cnio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Centro Nacional De Investigaciones Oncologicas Cnio filed Critical Fundacion Centro Nacional De Investigaciones Oncologicas Cnio
Publication of JP2013542720A publication Critical patent/JP2013542720A/ja
Publication of JP2013542720A5 publication Critical patent/JP2013542720A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013528731A 2010-09-21 2011-09-20 抗エフリン−ｂ２抗体およびその使用 Pending JP2013542720A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201031402A ES2378976B1 (es) 2010-09-21 2010-09-21 Anticuerpo contra ephrin b2 y su uso.
ESP201031402 2010-09-21
PCT/ES2011/070655 WO2012038573A1 (es) 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso

Publications (2)

Publication Number Publication Date
JP2013542720A true JP2013542720A (ja) 2013-11-28
JP2013542720A5 JP2013542720A5 (https=) 2014-11-06

Family

ID=45873482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013528731A Pending JP2013542720A (ja) 2010-09-21 2011-09-20 抗エフリン−ｂ２抗体およびその使用

Country Status (12)

Country Link
US (1) US9062109B2 (https=)
EP (1) EP2620449A4 (https=)
JP (1) JP2013542720A (https=)
KR (1) KR20140014062A (https=)
CN (1) CN103237812A (https=)
AU (1) AU2011306816A1 (https=)
BR (1) BR112013005977A2 (https=)
CA (1) CA2812727A1 (https=)
ES (1) ES2378976B1 (https=)
MX (1) MX2013003168A (https=)
RU (1) RU2013118454A (https=)
WO (1) WO2012038573A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516611A (ja) * 2018-12-28 2022-03-01 ザ ジェネラル ホスピタル コーポレイション 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694477B (zh) * 2015-03-03 2018-04-17 西安交通大学 一种EphrinB2高表达的重组HEK293细胞及其应用
EP3969478A1 (en) * 2019-05-14 2022-03-23 Sanford Health Anti-human ephrin b1 antibodies and uses thereof
WO2020242910A1 (en) * 2019-05-24 2020-12-03 The Regents Of The University Ofcalifornia Compositions and methods for treating cancer
WO2025207820A2 (en) * 2024-03-27 2025-10-02 Mediar Therapeutics, Inc. Anti-ephrin b2 antibodies and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006022295A1 (ja) * 2004-08-24 2006-03-02 Kyowa Hakko Kogyo Co., Ltd. 抗エフリンb2抗体
WO2007127506A2 (en) * 2006-01-20 2007-11-08 Genentech, Inc. Anti-ephrinb2 antibodies and methods using same
WO2010019565A2 (en) * 2008-08-12 2010-02-18 Medlmmune, Llc Anti-ephrin b2 antibodies and their use in treatment of disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531684C (en) * 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
AU2006308648A1 (en) * 2005-10-31 2007-05-10 Duke University Antibodies and immunotoxins that target human glycoprotein NMB
ES2368764T3 (es) * 2007-03-19 2011-11-22 Universität Stuttgart ANTAGONISTAS SELECTIVOS DE huTNFR1.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006022295A1 (ja) * 2004-08-24 2006-03-02 Kyowa Hakko Kogyo Co., Ltd. 抗エフリンb2抗体
WO2007127506A2 (en) * 2006-01-20 2007-11-08 Genentech, Inc. Anti-ephrinb2 antibodies and methods using same
WO2010019565A2 (en) * 2008-08-12 2010-02-18 Medlmmune, Llc Anti-ephrin b2 antibodies and their use in treatment of disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015036022; ＷＡＮＧ　Ｙｉｎｇｄｉ　ｅｔ　ａｌ．: Ｎａｔｕｒｅ Ｖｏｌ．　４６５，　Ｎｏ．　７２９７, 20100527, ｐ．　４８３-４８６, Ｍａｃｍｉｌｌａｎ　Ｐｕｂｌｉｓｈｅｒｓ　Ｌｉｍｉｔｅｄ． *
JPN6015036025; ＭＡＯ　Ｗｅｉｇｕａｎｇ　ｅｔ　ａｌ．: Ｃａｎｃｅｒ　Ｒｅｓ． Ｖｏｌ．　６４，　Ｎｏ．　３, 20040201, ｐ．　７８１-７８８, Ａｍｅｒｉｃａｎ　Ａｓｓｏｃｉａｔｉｏｎ　ｆｏｒ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516611A (ja) * 2018-12-28 2022-03-01 ザ ジェネラル ホスピタル コーポレイション 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体

Also Published As

Publication number Publication date
US9062109B2 (en) 2015-06-23
ES2378976A1 (es) 2012-04-19
MX2013003168A (es) 2013-08-21
KR20140014062A (ko) 2014-02-05
EP2620449A4 (en) 2014-03-26
CN103237812A (zh) 2013-08-07
EP2620449A1 (en) 2013-07-31
WO2012038573A1 (es) 2012-03-29
ES2378976B1 (es) 2013-05-06
US20130287795A1 (en) 2013-10-31
CA2812727A1 (en) 2012-03-29
RU2013118454A (ru) 2014-10-27
BR112013005977A2 (pt) 2019-09-24
AU2011306816A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
CN108602888B (zh) 抑制癌症生长的结合分子
JP5719596B2 (ja) 抗体及びその誘導体
WO2016023001A1 (en) Multispecific high affinity pd-1 agents and methods of use
KR20140125351A (ko) 항-cd98 항체 및 이의 사용 방법
CN109988240B (zh) 抗gpc-3抗体及其用途
JP2021508683A (ja) 抗ｌｒｐ５／６抗体及び使用方法
CN119053624A (zh) 生长激素受体靶向多肽
JP2013542720A (ja) 抗エフリン−ｂ２抗体およびその使用
JP2024079697A (ja) 骨の疾患の治療に用いるためのトランスフェリン受容体２のアンタゴニスト及びアゴニスト
CN110627905B (zh) 靶向vegf与egfr的双功能融合蛋白及其应用
CN111629752B (zh) 用于预防或治疗细胞迁移相关疾病的含作为有效成分的与赖氨酰-tRNA合成酶N-末端特异性结合的抗体的药物组合物
CN114245805A (zh) Alk7结合蛋白及其用途
WO2023016509A1 (zh) 抑制肿瘤细胞转移的药物及其用途
US20220195037A1 (en) Compositions and methods for inhibiting cancer stem cells
US20210155709A1 (en) Antibodies anti tumor associated antigens and method for obtaining them
CN107614524A (zh) 治疗
CN112601551A (zh) 抗海蟾蜍毒素抗体及其应用
CN110734494B (zh) 抗tspan8单克隆抗体及其用途
US11945858B2 (en) Antibodies and antibody fragments against HNAV1.7 channel and their use in pain and cancer indications
US20240025985A1 (en) Agent for Preventing or Treating Frontotemporal Lobar Degeneration
KR20250123919A (ko) 항-tgf베타 수용체 1 항체 및 그의 용도
HK40003020A (en) Alk7 binding proteins and uses thereof
EA051189B1 (ru) Связывающие молекулы, которые ингибируют рост рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160223